{"hq_id":"hq-p-spe-000070","name":"Chemotherapy Drug Preparation and Administration (Cytotoxic Exposure)","category":{"primary":"specialty","secondary":"healthcare","tags":["chemotherapy","cytotoxic","hazardous drug","pharmacy","USP 800","surface contamination"]},"product_tier":"SPE","overall_risk_level":"severe","description":"Occupational exposure to hazardous antineoplastic drugs during pharmacy compounding, nursing administration, and environmental surface contamination. Cyclophosphamide, 5-FU, and other cytotoxic agents detected on pharmacy counters, IV poles, patient bedrails, and even toilet seats in patient rooms. Healthcare workers handling chemotherapy have elevated urinary mutagenicity, increased spontaneous abortion risk, and documented chromosomal damage. USP <800> (2019) sets standards for handling.","synthesis":{"derived_risk_level":"extreme","synthesis_confidence":0.738,"synthesis_method":"compound_composition","context_used":"occupational_exposure","context_source":"product_users","exposure_modifier":1.265,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"sensitive_populations":"pharmacy staff, oncology nurses, pregnant healthcare workers","overall_risk":"severe","primary_concerns":["Cytotoxic drug surface contamination detectable even in compliant facilities","Increased spontaneous abortion risk in exposed healthcare workers","Chromosomal damage documented in pharmacy compounding staff","Mutagenic urinary metabolites in exposed workers"],"exposure_routes":"Dermal (surface contamination); inhalation (aerosol during compounding); oral (hand-to-mouth)"},"exposure":{"routes":["dermal","inhalation","oral"],"contact_types":["skin_brief","inhalation","oral_direct"],"users":["occupational"],"duration":"hours","frequency":"daily","scenarios":["Pharmacy compounding of IV chemotherapy (aerosol generation during mixing)","Nursing administration of cytotoxic drugs (IV bag priming, disconnection)","Surface contamination on counters, door handles, toilet seats in patient areas","Laundry handling of chemo-contaminated linens and gowns"],"notes":"NIOSH Alert (2004): recommends closed-system transfer devices (CSTDs), biological safety cabinets, double gloving, and environmental decontamination. USP <800> (2019): mandatory standards for handling hazardous drugs — requires designated areas, PPE, CSTDs, medical surveillance. Studies show detectable cyclophosphamide on pharmacy surfaces even in facilities following guidelines."},"consumer_guidance":{"usage_warning":"Healthcare facilities: implement USP <800> requirements. Use closed-system transfer devices (CSTDs) for all hazardous drug handling. Double-glove with chemotherapy-tested gloves. Provide medical surveillance for exposed workers. Pregnant workers should not handle cytotoxic drugs.","safer_alternatives":["Closed-system transfer devices (PhaSeal, Equashield)","Biological safety cabinet (Class II, B2) for compounding","Robot-assisted compounding (reduces human exposure)","Environmental surface monitoring and decontamination protocols"],"red_flags":[{"indicator":"Exposure without required PPE or engineering controls","meaning":"Risk of acute injury or chronic disease.","action":"Follow OSHA requirements and manufacturer PPE recommendations."}],"green_flags":[{"indicator":"OSHA-compliant engineering controls and PPE in use","meaning":"Exposure controlled to below permissible limits.","verification":"Check for OSHA compliance documentation and exposure monitoring records."}],"what_to_ask":[{"question":"What are the OSHA-required exposure controls for this product/process?","why_it_matters":"OSHA PELs and engineering controls are legally mandated.","good_answer":"Specific PEL, engineering controls, and PPE identified and implemented.","bad_answer":"No awareness of OSHA requirements."}],"alternatives":[{"name":"Closed-system transfer devices","notes":"PhaSeal, Equashield"},{"name":"Biological safety cabinet","notes":"Class II, B2) for compounding"},{"name":"Robot-assisted compounding","notes":"reduces human exposure"}]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"USP <800> Hazardous Drugs — Handling in Healthcare Settings","citation":"USP General Chapter <800>","requirements":"Engineering controls, PPE, CSTDs, designated areas, medical surveillance, environmental monitoring for all hazardous drug handling.","compliance_status":null,"effective_date":"2019-12-01","enforcing_agency":"State boards of pharmacy","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Cytotoxic waste: dedicated hazardous waste stream per EPA/state regulations.","hazardous_waste":true,"expected_lifespan":"varies"},"formulation":{"form":"varies","key_ingredients":[{"hq_id":"hq-c-org-000110","name":"Cyclophosphamide","role":"example_cytotoxic","concentration_pct":"varies"}],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000110","compound_name":null,"role":"example_cytotoxic","typical_concentration":"varies"}],"identifiers":{"common_names":["chemotherapy drug preparation and administration (cytotoxic exposure)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[{"brand":"3M","manufacturer":"3M","market_position":"mass_market","notable":"Safety and specialty product conglomerate"},{"brand":"Honeywell","manufacturer":"Honeywell","market_position":"mass_market","notable":"Safety equipment and technology"},{"brand":"DuPont","manufacturer":"DuPont","market_position":"professional","notable":"Chemical and safety products"}],"brand_examples_disclaimer":"Representative branded products of this category. Concerning ingredients listed in materials.concerning[] apply to the category, not necessarily to every named brand. Specific formulations vary by SKU and may have changed since this record was written; consult the brand's current ingredient label before drawing brand-level conclusions.","sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-25"},{"type":"regulation","title":"USP <800> Hazardous Drugs — Handling in Healthcare Settings (USP General Chapter <800>)","jurisdiction":"USA","year":2019,"citation":"USP General Chapter <800>","id":"src_99d23496"},{"id":"iarc_100a_cyclophosphamide","type":"regulatory","title":"IARC Monographs Volume 100A: Pharmaceuticals — Cyclophosphamide, Group 1 Classification (Bladder Cancer, AML/MDS; Acrolein Mechanism)","year":2012,"inherited_from_compound":"hq-c-org-000110"},{"id":"fda_cyclophosphamide_prescribing","type":"regulatory","title":"US FDA: Cyclophosphamide Prescribing Information — Indications, Dosing, Myelosuppression, Hemorrhagic Cystitis, Teratogenicity, and Secondary Malignancy Warnings","year":2021,"inherited_from_compound":"hq-c-org-000110"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-25","timestamp":"2026-05-14T01:24:07.390Z"}}